Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

Gilead Sciences’ Tro Delvy Fails to Meet Primary Endpoint in ASCENT‑07 Metastatic Breast Cancer Trial

Fineline Cube Nov 10, 2025

Gilead Sciences Inc. (NASDAQ: GILD) today disclosed that the Phase III ASCENT‑07 study, which compared Trodelvy...

Company Deals

Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance

Fineline Cube Nov 10, 2025

Insilico Medicine, a leader in artificial‑intelligence‑powered drug discovery, today announced a strategic collaboration with Eli Lilly (NYSE:...

Company Deals

SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases

Fineline Cube Nov 10, 2025

SanegeneBio, a biotechnology company specializing in RNAi therapeutics, today announced a global research collaboration and...

Company Deals

DeliNova Raises Nearly RMB 60 Million in Seed & Angel Financing for In‑Vivo CAR‑T Platform

Fineline Cube Nov 10, 2025

Nantong DeliNova Therapeutics Co., Ltd. announced today the successful closing of a seed‑stage financing round...

Company Deals

Organon Acquires JADA System from Laborie for USD 465 Million

Fineline Cube Nov 10, 2025

Organon Inc. (NYSE: OGN) announced today that it has entered into an agreement with Laborie...

Company Deals Digital

HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration

Fineline Cube Nov 10, 2025

HBM Holdings Limited (HKG: 2142) and Evinova, an independent health‑tech arm of the AstraZeneca Group,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Announces HRS‑2430 Injection Approval for Clinical Trials

Fineline Cube Nov 10, 2025

China‑listed Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous...

Others

National Health Commission’s Negative Behavior List for Medical Staff Internet‑Based Health Science Popularization (Trial)

Fineline Cube Nov 10, 2025

The National Health Commission (NHC) announced on 7 November 2025 a “Negative Behavior List for Medical Staff...

Company Deals

Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal

Fineline Cube Nov 10, 2025

Novo Nordisk A/S (NYSE: NVO) confirmed today that it will not pursue an increased offer...

Company Deals

Aureka Biotechnologies Closes Multi‑Million‑Dollar Series A – Generative Antibody Platform Gains 5Y Capital & Qiming Backing

Fineline Cube Nov 10, 2025

Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of...

Company Deals

Zhaoke Ophthalmology Indonesia Distribution Deal – BRIMOCHOL PF Eyes on Market Expansion

Fineline Cube Nov 8, 2025

China‑listed Zhaoke Ophthalmology Ltd. (HKG: 6622) announced a new distribution and supply agreement with Indonesia’s...

Company Deals

Shanghai‑Boehringer Ingelheim MOU Launches Stroke Prevention Initiative – Strengthening China Health 2030

Fineline Cube Nov 8, 2025

During the 8th China International Import Expo (CIIE), the Shanghai Medical Association (SMA) and Boehringer Ingelheim...

Company Deals Hospital

Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative

Fineline Cube Nov 8, 2025

Boehringer Ingelheim announced at the 8th China International Import Expo (CIIE) that it has signed...

Company

Zai Lab Q3 2025 Revenue Up 13% YoY to $115.4 M, Led by Nuzyra and Xacduo; Zejula Slows

Fineline Cube Nov 8, 2025

Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third‑quarter 2025 financial results, reporting total...

Company Deals

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders

Fineline Cube Nov 8, 2025

In a high‑profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:...

Policy / Regulatory

NHSA Pilot AI Review Accelerates Full‑Process Medical Insurance Assessment in 7 Chinese Provinces

Fineline Cube Nov 8, 2025

The National Healthcare Security Administration (NHSA) has announced a three‑phase, AI‑powered review pilot covering Beijing,...

Policy / Regulatory

US FDA’s CNPV Fast‑Track Program Expands to 15 Drugs, Cutting Review Time to Months

Fineline Cube Nov 8, 2025

The Commissioner’s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two‑batch...

Company Deals

Sichuan Biokin Launches on HKEX, Raises HK$3.3 B in $389/Share Offering – A Milestone for China’s Biotech

Fineline Cube Nov 8, 2025

China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its successful initial public offering (IPO)...

Medical Device

LifeTech Scientific Secures NMPA Approval for G‑Branch TAAA Stent‑Graft System

Fineline Cube Nov 8, 2025

LifeTech Scientific Corporation (HKG: 1302) announced that China’s National Medical Products Administration (NMPA) has granted...

Company

Viatris Posts Q3 2025 Revenue Dip, Highlights Emerging‑Market Branded Growth and Aculys Pharma Acquisition

Fineline Cube Nov 8, 2025

U.S.‑based Viatris Inc. (NASDAQ: VTRS) released its third‑quarter 2025 earnings, showing a 2 % year‑over‑year (YOY)...

Posts pagination

1 … 134 135 136 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.